Sildenafil treatment attenuates ventricular remodeling in an experimental model of aortic regurgitation

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary

(2014) Rick A. Nishimura et al.   CIRCULATION

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

(2013) Margaret M. Redfield et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hypertrophy Signaling Pathways in Experimental Chronic Aortic Regurgitation

(2013) Niels Thue Olsen et al.   Journal of Cardiovascular Translational Research

Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation

(2012) Kyung-Hee Kim et al.   CIRCULATION

Guidelines on the management of valvular heart disease (version 2012)

(2012) et al.   EUROPEAN HEART JOURNAL

Differential Cardiac Remodeling in Preload Versus Afterload

(2010) Karl Toischer et al.   CIRCULATION

Valvular Heart Disease: Diagnosis and Management

(2010) Kameswari Maganti et al.   MAYO CLINIC PROCEEDINGS

Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies

(2010) Bianca C. Bernardo et al.   PHARMACOLOGY & THERAPEUTICS

Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice

(2009) Peter Pokreisz et al.   CIRCULATION

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

(2009) Emily J. Tsai et al.   PHARMACOLOGY & THERAPEUTICS

2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease

(2008) Robert O. Bonow et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY